Mark Ferguson to Esophageal Neoplasms
This is a "connection" page, showing publications Mark Ferguson has written about Esophageal Neoplasms.
Connection Strength
2.945
-
50th Anniversary Perspective on Groves LK. Carcinoma of the Esophagus-1965: evaluation of treatment. Ann Thorac Surg 1965;1:416-31. Ann Thorac Surg. 2015 Apr; 99(4):1116-8.
Score: 0.410
-
Invited commentary. Ann Thorac Surg. 2010 Sep; 90(3):926.
Score: 0.299
-
Esophageal resection for high-grade dysplasia and intramucosal carcinoma: When and how? World J Gastroenterol. 2010 Aug 14; 16(30):3786-92.
Score: 0.298
-
Induction therapy does not increase surgical morbidity after esophagectomy for cancer. Ann Thorac Surg. 2004 Nov; 78(5):1783-9.
Score: 0.199
-
Long-term survival after esophagectomy for Barrett's adenocarcinoma in endoscopically surveyed and nonsurveyed patients. J Gastrointest Surg. 2002 Jan-Feb; 6(1):29-35; discussion 36.
Score: 0.164
-
Risk Prediction Model of 90-Day Mortality After Esophagectomy for Cancer. JAMA Surg. 2021 09 01; 156(9):836-845.
Score: 0.160
-
Resection for Barrett's mucosa with high-grade dysplasia: implications for prophylactic photodynamic therapy. J Thorac Cardiovasc Surg. 1997 Nov; 114(5):824-9.
Score: 0.123
-
Esophageal perforation and caustic injury: management of perforated esophageal cancer. Dis Esophagus. 1997 Apr; 10(2):90-4.
Score: 0.118
-
Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer. J Thorac Oncol. 2017 01; 12(1):36-42.
Score: 0.114
-
Doubling of 30-Day Mortality by 90 Days After Esophagectomy: A Critical Measure of Outcomes for Quality Improvement. Ann Surg. 2016 Feb; 263(2):286-91.
Score: 0.109
-
BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol. 2015 May; 110(5):662-82; quiz 683.
Score: 0.103
-
Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol. 1995 Mar; 2(2):101-6.
Score: 0.102
-
External validation of the Ferguson pulmonary risk score for predicting major pulmonary complications after oesophagectomy†. Eur J Cardiothorac Surg. 2016 Jan; 49(1):333-8.
Score: 0.102
-
Complete endoscopic mucosal resection is effective and durable treatment for Barrett's-associated neoplasia. Clin Gastroenterol Hepatol. 2014 Dec; 12(12):2002-10.e1-2.
Score: 0.096
-
Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res. 2013 Jan 01; 73(1):184-94.
Score: 0.087
-
Adenocarcinoma in Barrett's esophagus. Semin Thorac Cardiovasc Surg. 1992 Oct; 4(4):276-9.
Score: 0.086
-
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012 Aug; 143(2):336-46.
Score: 0.084
-
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Med Oncol. 2011 Dec; 28 Suppl 1:S152-61.
Score: 0.074
-
Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? Clin Gastroenterol Hepatol. 2008 Feb; 6(2):159-64.
Score: 0.062
-
Strangulation of the reconstructive gastric tube by the azygos arch. Ann Thorac Surg. 2006 Aug; 82(2):e8-10.
Score: 0.056
-
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.
Score: 0.036
-
Induction chemotherapy, surgery, and concomitant chemoradiotherapy for carcinoma of the esophagus: a long-term analysis. Ann Oncol. 1998 Jun; 9(6):647-51.
Score: 0.032
-
Treatment of carcinoma of the proximal esophagus. Surg Gynecol Obstet. 1989 Apr; 168(4):307-10.
Score: 0.017
-
Barrett's esophagus. Adv Surg. 1988; 21:127-55.
Score: 0.016